Novo Nordisk market cap surpasses Tesla on new obesity pill trial data

Home » Blog » Novo Nordisk market cap surpasses Tesla on new obesity pill trial data

March 9, 2024March 9, 2024

Wegovy obesity drug maker Novo Nordisk surpassed Tesla in market value Thursday after fresh early trial data showed positive results for its new experimental weight loss pill.

Previous PostKnow Your Prospect (KYP): What’s in Their Portfolio and Why?Next PostHelloFresh shares dive 42% after meal kit giant warns on outlook

Latest Articles

AI and crypto drove gains in this year’s top 5 tech stocks
Nvidia sees ‘remarkable’ influx of retail investor dollars as traders flock to AI darling
Japan stocks rise as government reportedly set to propose record budget
Asia’s year in review: Who had it good — and who had it bad — in 2024
Stocks making the biggest moves midday: American Airlines, Broadcom, big banks and more
Biggest banks sue the Federal Reserve over annual stress tests
Digital health companies got pummeled by Wall Street in 2024 as industry adapts to post-Covid slowdown
Nissan could face cost-cutting ‘carnage’ in Honda merger, Carlos Ghosn says
European markets close higher ahead of Christmas shutdown; Novo Nordisk resumes recovery
Why the ‘great resignation’ became the ‘great stay,’ according to labor economists

Advertising

GTR provides global news on topics ranging from world markets, investing opportunities, industry analysis and so much more.

News

Finance
Investments
Technology

Countries

Worldwide
Africa
Asia
Australia
Canada
Europe
United States

Official

Magazines
Videos
About Us
Contact Us
Privacy
Terms & Conditions